NCT03776227View on ClinicalTrials.gov

A Bioequivalence Study Testing Two Formulations of Sotagliflozin in Healthy Male and Female Subjects Under Fasted Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

January 25, 2019

Primary Completion Date

April 22, 2019

Study Completion Date

April 22, 2019

Conditions
Type 2 Diabetes MellitusHealthy Subjects
Interventions
DRUG

sotagliflozin (SAR439954)

"Pharmaceutical form: tablet~Route of administration: oral"

Trial Locations (1)

33014

Investigational Site Number 8400001, Miami

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT03776227 - A Bioequivalence Study Testing Two Formulations of Sotagliflozin in Healthy Male and Female Subjects Under Fasted Conditions | Biotech Hunter | Biotech Hunter